Feedback / Questions
QTORIN 3.9% (rapamycin topical) - Palvella Therapeutics
https://www.globenewswire.com/news-release/2025/06/23/3103284/0/en/Palvella-Therapeutics-Completes-Enrollment-in-Phase-3-SELVA-Trial-of-QTORIN-Rapamycin-for-Microcystic-Lymphatic-Malformations-Exceeding-Enrollment-Target-by-Over-25.html
Jun 23, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next